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Abstract. The aim of the present study was to investigate the sub-acute toxicological effects of Jobelyn® on pregnant 
albino rats by employing biochemical, haematological and histopathological methods. A total of 32 pregnant female rats 
were randomly assigned to four different groups of eight rats each. The control group received distilled water and 
different doses of Jobelyn®; 250, 500, 1000 mg kg-1were administered orally once a day for 2 weeks to the other groups. 
Biochemical analysis revealed a significant decrease (p<0.05) in the levels of alanine aminotransferase, albumin, urea, 
PCV and Hb in the treatment groups when compared to the control. However, the significant decrease in PCV and Hb 
was observed solely in the group treated with 1000 mg kg-1body weight, suggesting that this decrease could be dose-
dependent. Alkaline phosphatase, total protein, triglycerides, cholesterol, HDL cholesterol, LDL cholesterol, eosinophils, 
basophils, neutrophils, monocytes, lymphocytes, WBC count, revealed no significant difference (p<0.05) when compared 
to the control. The results show that at an appropriate dosage, the use of Jobelyn® during pregnancy may have no adverse 
effect on the liver and kidney tissues and may possess hepatoprotective and nephroprotective properties however the 
histopathological studies revealed that very high levels of Jobelyn may be hepatotoxic. 
INTRODUCTION 
Jobelyn® is a multifunctional natural ingredient derived from the leaf sheaths of Sorghum bicolor, a member of 
the Poaceae family [1].All parts of the plant, Sorghum (bicolor) have been useful in disease treatment, making the 
plant a phytoceutical. The leaf sheath of Sorghum bicolor is commonly used as a remedy against anaemia by 
traditional medicine healers [2]. The root is used in treating malaria in Southern Rhodesia; the seed has been 
employed for the treatment of breast disease and diarrhoea while the stem has been used for tubercular swellings 
treatment [3]. Recently, focus has been on the leaf sheath of S. bicolor being used as herbal remedy for anaemia and 
having a boosting effect on blood concentration; possessing hematinic potentials [2, 4]. This powder extract from 
Sorghum bicolor(Jobelyn®), contains proteins, carbohydrates, dietary fibre as well as bioactive substances known as 
phytochemicals, which have the potential to significantly affect human health positively [5]. The high concentration 
of phytochemicals, including proanthocyanidins, anthocyanins, phenolic acids, apigenin, proapigeninidin, 
apigeninidin, luteolin, naringenins in this wholly, natural, herbal product confers on it, very high antioxidant activity 
with a total oxygen radical absorbance capacity (ORAC) score of 37,000 μmolTE/g of dry powder[6]. It is capable 
of inhibiting peroxyl free radicals, hydroxyl free radicals, singlet oxygen and possesses a high capacity for 
quenching superoxide anions, hence its usefulness in maintaining human health [7]. The inhibition of peroxyl free 
radicals per gram of jobelyn® is 3,549 μmoleTE/g as compared to 997, 68, 24, 15, 8 and 7 μmoleTE/g of acai berry, 
cherry tart, blueberry, strawberry, oranges, red grape, respectively [8].This indicates that the antioxidant capacity of 
Jobelyn® is about 4 times higher than that of acai berry and 50 times than that of tart cherries [8] thussignifying the 
antiradical properties of Jobelyn® [9]. This herbal formulation is believed to alleviate symptoms of anaemia of 
diverse origin, among which are malaria, sickle cell disease, leukaemia, stroke, arthritis, pregnancy, enteric fever, 
helminthiasis, multiple myeloma, and tuberculosis, its use in pregnancy being quite notable [1, 10]. Elevation of 
packed cell volume (PCV) from 21 percent to 32 per cent has been observed in pregnant women within eight days of 
ectopic pregnancy operation following the use of Jobelyn® [unpublished]. Despite the wide use of this herbal 
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formulation, there is a paucity of studies on its toxicological profile. In relation to its effect on pregnant women, 
there has been no previous work done to ascertain if it poses health risks on the mother or not.  The plethora of 
previously reported and unreported adverse drug reactions associated with the use of herbal medicines makes it 
imperative that pre-clinical toxicological studies be carried out on these natural products [11]. Furthermore, the 
recommendation of the herbal drug as a dietary supplement, establishes the need for toxicological studies on its 
effects on pregnant women. The primary aim of the present study was to investigate the sub-acute toxicological 
effect of Jobelyn® by employing the biochemical, haematological, and histological indices in pregnant albino Wistar 
rats. 
MATERIALS AND METHODS 
A total of thirty two healthy cyclic female Wistar albino rats weighing 82-190 g were used in this study. Animals 
were acclimatized for two weeks prior to commencement of treatment housed under standard environmental 
conditions and fed with a standard rat diet (obtained from Graceline feeds, Ota, Ogun state) with free access to 
water. During this period of acclimatization, the animals were exposed to a photoperiodicity of 12h light/12h 
darkness and were periodically assessed for gross morphological/behavioural changes.  
Experimental Design 
The animals were divided into 4 groups of 8 rats each and treated daily for 2 weeks; beginning from the 5th to 
19th day of gestation during the period of foetal organogenesis. Group I served as the control group and received 
distilled water while groups II, III and IV received 250, 500 and 1000 mg kg-1of Jobelyn®. All animals were 
weighed and sacrificed on the 20th day of pregnancy. Their uteri were dissected and blood samples were 
immediately collected. The liverand kidney was collected, trimmed of excess fat and weighed and a portion was 
separated for histological studies. 
Haematological assays 
Blood samples were withdrawn from the heart to measure the levels of haemoglobin (Hb), packed cell volume 
(PCV), white blood cell count (WBC), WBC differentials (neutrophils, monocytes, lymphocytes, basophils and 
eosinophil) [12] 
Biochemical assays 
The commercial test kits for liver function test were purchased from Randox Laboratory, United Kingdom. 
Standard procedures were used to evaluate the protein concentration [13], aspartate aminotransferase (AST) [14], 
alkaline phosphatase (ALP) [15], alanine aminotransferase (ALT)[16],  albumin[17], direct bilirubin [18], urea[19] 
and creatinine[20]. 
Histopathological studies 
The organtissues were fixed in normal saline for a period of 72 h and cut into thin slices 2.1 mm thick. The 
tissues were dehumidified using liquor. They were thereafter treated with paraffin wax and cast into blocks; tissue 
sectionswere then slit into 5μm using microtome and allowed to dry on a slide. The slides were afterwards soiled 
with haematoxylin-eosin stain, analyzed using a light microscope and photomicrographs recorded [21]. 
Statistical analysis 
Differences between means of biochemical and haematological analysis of all the groups were estimated using a 
one-way analysis of variance followed by least significant difference test (post hoc) using the SPSS software (SPSS 
15 for Windows). The p<0.05 were considered statistically significant. Graph pad prism was used in presentation of 
charts. 
RESULTS 
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TABLE 1. Effect of Jobelyn® on Weight of Selected Organs of Pregnant Albino Rats 
Parameters Control (A)   250 mg kg-1 (B)   500 mg kg-1 (C)  1000 mg kg-1 (D) 
LIVER 5.97+0.53 6.03+0.87 6.27+0.45 5.24+0.77 
KIDNEY 0.47+0.03 0.47+0.04 0.47+0.02 0.46+0.02 
HEART 0.45+0.03 0.47+0.04 0.49+0.02 0.49+0.04 
LUNGS 1.13+0.09 1.13+0.13 1.29+0.06 1.15+1.15 
BRAIN 1.41+0.06 1.16+0.18 1.32+0.04 1.35+0.05 
SPLEEN 0.58+0.06 48.50+5.74 0.76+0.05 1.02+0.18 
Values represent mean + SEM of 8 replicates. From the Table 1, there was no significant difference p<0.05 in 
the weight of the kidney, heart, lungs, brain, spleen of treatment groups administered with Jobelyn® when compared 
with the control group. 
TABLE 2. Effect of Jobelyn® on in Liver Homogenate of Pregnant Albino Rats. 
Parameters Control (A) 250 mg kg-1 (B) 500 mg kg-1 (C) 1000 mg kg-1 (D) 
ALT (U/I) 94.09+5.01 90.54+1.42 86.57+1.12 88.16+1.84 
ALP (U/I) 104.420+23.26 237.65+127.25 77.54+14.93 140.66+66.50 
AST (U/I) 118.21+4.10 103.25+17.63 117.02+15.01 136.59+2.57 
TP (mg/dl) 2.08+0.41 2.20+0.43 1.79+0.35 1.55+0.28 
ALB (mg/dl) 0.61+0.12 0.65+0.89 0.44+0.08 0.57+0.10 
Values represent mean + SEM of 8 replicates p<0.05, significantly different from the control group. ALT = 
Alanine aminotransferase, ALP =Alkaline phosphatase, AST = Aspartate aminotransferase, TP = Total protein, 
ALB = Albumin, D BIL=Direct Bilirubin. From Table 2, there was no significant difference p<0.05 in the activity of 
ALT, ALP, AST, TP, Albumin and Direct Bilirubin in the liver homogenate of groups administered Jobelyn® when 
compared with the control group. 
TABLE 3. Effect of Jobelyn® in Kidney Homogenate of Pregnant Albino Rats. 
Parameters Control (A) 250 mg kg-1 (B) 500 mg kg-1 (C) 1000 mg kg-1 (D) 
UREA (mg/dl) 27.22+1.64 20.98+1.92 10.39+2.63 25.50+9.96 
CREA (mg/dl) 1.83+0.32 1.75+0.32 1.27+0.31 1.55+0.48 
Values represent mean + SEM of 8 replicates p<0.05, not significantly different from the control group. CREA = 
Creatinine. From Table 3, there was no significant difference p<0.05 in the levels of urea and creatinine in the 
kidney homogenate of the treatment groups administered with Jobelyn® when compared with the control group. 
TABLE 4. Eect of Jobelyn® on Selected Lipid Profile Parameters in Plasma of Pregnant Albino Rats. 
Parameters Control (A) 250 mg kg-1 (B) 500 mg kg-1 (C) 1000 mg kg-1 (D) 
TRIGS (mg/dl) 47.02+10.33 41.53+8.05 52.60+8.51 43.48+14.48 
T.CHOL (mg/dl) 66.66+8.19 48.16+1.34 59.26+4.46 53.84+5.90 
Values represent mean + SEM of 8 replicates p<0.05, not significantly different from the control group. TRIGS 
= Triglycerides, T. CHOL = Total Cholesterol. From Table 4, there was no significant difference p<0.05 in the 
levels of Triglycerides and Total cholesterol in the plasma of the treatment groups administered with Jobelyn® when 
compared with the control group. 
TABLE 5. Effect of Jobelyn® on Selected Lipid Profile Parameters in Liver homogenate of Pregnant Albino Rats.  
Parameters Control (A) 250 mg kg-1 (B) 500 mg kg-1 (C) 1000 mg kg-1 (D) 
TRIGS (mg/dl) 119.52+13.88 102.93+11.85 102.33+9.93 146.34+23.26 
T.CHOL (mg/dl) 25.00+5.01 23.41+3.00 36.95+8.20 32.48+9.29 
HDL CHOL (mg/dl) 206.89+3.73 201.80+0.83 202.77+0.90 207.11+6.76 
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Values represent mean + SEM of 8 replicates p<0.05, not significantly different from the control group. TRIGS 
= Triglycerides, TOTAL CHOL = Total Cholesterol, HDL CHOL = High Density Lipoprotein Cholesterol. From 
Table 5, there was no significant difference p>0.05 in the levels of Triglycerides, Total cholesterol and HDL 
cholesterol in the liver homogenate of the treatment groups administered with Jobelyn® when compared with the 
control group. 
TABLE 6. Effect of Jobelyn® on Selected Lipid Profile Parameters in Kidney of Pregnant Albino Rats. 
Parameters Control (A) 250 mg kg-1 (B) 500 mg kg-1 (C) 1000 mg kg-1 (D) 
TRIGS (mg/dl) 60.24+2.95 60.70+7.55 56.20+3.50 54.52+3.19 
T.CHOL (mg/dl) 48.16+3.32 39.94+3.47 52.46+6.95 42.58+6.31 
HDL CHOL (mg/dl) 21.19+6.11 15.77+3.60 14.74+1.98 14.62+1.31 
Values represent mean + SEM of 8 replicates p<0.05, not significantly different from the control group. TRIGS 
= Triglycerides, TOT CHOL = Total Cholesterol, HDL CHOL = High Density Lipoprotein Cholesterol. From Table 
6, there was no significant difference p<0.05 in the levels of Triglycerides, Total cholesterol and HDL cholesterol in 
the kidney homogenate of the treatment groups administered with Jobelyn® when compared with the control group. 
TABLE 7. Effect of Jobelyn® on Haematological Parameters in Plasma of Pregnant Rats. 
Parameters Control 250 mg kg-1 500 mg kg-1 1000 mg kg-1 
EOSINO (x 1012/L) 41.00+3.49 34.80+4.76 38.11+1.88 40.29+4.14 
NEUTRO (x1012/L) 46.50+1.55 56.80+5.32 52.67+1.70 54.50+2.81 
BASO (x 1012/L) 4.0+1.73 3.4+1.03 2.25+0.37 1.86+0.55* 
LYMPH (%) 4.25+0.63 5.00+1.30 5.22+0.97 3.83+1.08 
MONO (%) 1.50+0.29 1.0+0.0 1.57+0.30 1.40+0.24 
PCV (x 1012/L) 55.5+6.51 48.50+5.74 51.38+1.46 41.50+1.74* 
Hb (g/L) 17.90+2.10 15.65+1.85 16.57+0.47 13.39+0.56* 
Values represent mean + SEM of 8 replicates.*p<0.05: significantly different from the control group. WBC 
COUNT = White Blood Cell Count, NEUTRO = Neutrophils, EOSINO: =Eosinophils, BASO = Basophils, LYMPH 
= Lymphocytes, MONO = Monocytes, PCV: =Packed Cell Volume, Hb = Haemoglobin. From Table 7, there was 
no significant difference p<0.05 in the levels of neutrophils, eosinophils, basophils, lymphocytes, monocytes, white 
blood cell count, whereas, there was a significant difference p<0.05 in levels of haemoglobin and packed cell 
volume in the plasma of the treatment groups administered with Jobelyn® when compared with the control group. 
Histopathological examination 
In the histopathological examination, hepatoytes in control group revealed normal nuclei membrane, rough 
endoplasmic reticulum and mitochondria (Fig. 3A). But in the 250mg kg-1 group, mild to moderate portal 
inflammation was observed (Fig. 3B). The 500 mg kg-1 group (Figure 3C) revealed moderate inflammation, while 
moderate to severe portal inflammation was observed in the 1000 mg kg-1 (Fig. 3D). 
DISCUSSION 
Toxicological assessment of drugs, herbs and extracts are necessary to establish the safety limit of these 
substances in animals. These are then commonly used to assess the possible health risk in humans [22]. The liver is 
a metabolically active organ responsible for many vital life functions, some of such primary functions include; bile 
production and excretion; excretion of bilirubin, cholesterol, hormones, and drugs; metabolism of fats, proteins, and 
carbohydrates; storage of glycogen, vitamins, and minerals; synthesis of plasma proteins, such as albumin, and 
clotting factors, as well as blood detoxification and purification [23]. Due to these important activities, the liver is 
one of the body's organs most subject to injury. It is the central organ in the metabolism and detoxification of drugs 
and toxins. Consequently, drugs affect the liver more frequently than any other organ and place the liver at great risk 
for toxic damage [24]. The cells in the liver contain proteins called enzymes that drive these chemical reactions. 
When liver cells are damaged or destroyed, the enzymes in the cells leak out into the blood. Alanine 
aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP) are specific markers of 
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hepatic injury and hepatocellular necrosis [25]. A Significant decrease (P<0.05) in the activity of alanine 
aminotransferase (ALT) was observed in groups treated with 500 and 1000 mg/kg body weight of Jobelyn® when 
compared with the control (Fig 1). Hence, suggesting that Jobelyn® may possess hepatoprotective properties. ALT is 
localized in the cytosol of the hepatocytes and is a more sensitive marker of hepatocellular damage as opposed to 
AST which can also be produced from other tissues like heart, kidney and pancreas other than the liver [26]. 
However, AST and ALP levels were not significantly different (P<0.05) in the treated groups when compared with 
the control groups. A significant decrease (P<0.05) in albumin levels in the group administered 500 mg/kg body 
weight of Jobelyn® was observed (ig 1). A similar study conducted by Salawuet al. [27] and Mancini-Filho[28] 
revealed similar results.  The possible hepatoprotective effects of Jobelyn® could be attributed to the presence of 
significant levels of flavonoids such as tannins and anthocyanidins which help to clear up free radicals. It has been 
established that free radicals play a significant role in various pathogenesis, inflammatory diseases and can result in 
necrosis of the liver [29, 30]. Flavonoids are known for their ability to exhibit antioxidant potential, and their effects 
on human health and nutrition are considerable. The mechanisms of action of flavonoids are through chelating or 
scavenging processes [31]. Chemically, the remarkable antioxidant properties of flavonoids is due to the hydrogen 
donating substituents (hydroxyl groups), which are attached to the aromatic ring structures of flavonoids, enabling 
the flavonoids to undergo a redox reaction and thus helping them to rapidly scavenge free radicals easily. Flavonoids 
also mediate their antioxidant effect by a stable delocalization system, which consist of heterocyclic and aromatic 
rings as well as multiple unsaturated bonds, and helps to delocalize the resulting free radicals [32]. Finally, the 
presence of certain structural moieties which are capable of forming transition metal chelating complexes that can 
regulate the production of reactive oxygen species such as O2- and OH is also a mechanism through which 
flavonoids mediate their antioxidant effect [33]. Sorghum bicolour, the plant extract of Jobelyn® is known to possess 
high concentration of flavonoids which include tannins and anthocyanins, significantly possessing high 
concentrations of dimeric 3-deoxy-anthocyanidins [34, 35]. Phenolic compounds, which have also been found to 
exist in high concentrations in Sorghum bicolor [36] are considered to play an important role as dietary antioxidants 
for theprevention of oxidative damage in living system, further establishing the antiradical properties of 
Jobelyn®[36].Epidemiological studies have suggested association between the comsumption of phenolic acid - rich 
foods or beverages and the prevention of many diseases [37]. The potential hepatoprotective properties of this 
wholly herbal drug is further supported by the significant decrease (P<0.05) in albumin levels in the group 
administered 500 mg/kg body weight of Jobelyn®. This could have been pregnancy-induced, as albumin is often 
decreased in normal pregnancy as a consequence of haem dilution. It is noteworthy though, that a low albumin level 
is often temporary, and is not a reliable way to diagnose liver disease. In contrast, the concentrations of the 
transaminases (alanine and aspartate) and γ-glutamyltransferase normally increase during pregnancy. Thus, the 
decreased levels of ALT observed in pregnant rats treated with Jobelyn® is a further proof of the possible 
hepatoprotective effect of Jobelyn® The histological findings revealed mild to moderate portal inflammation in the 
liver of animals treated with 250 and 500 mg/kg bodyweight of Jobelyn®, while the liver of rat treated with 1000 
mg/kg bodyweight of Jobelyn® showed moderate to severe portal inflammation (Fig 3). This is possibly as a result 
of the dose of Jobelyn® administered to the animals as the severity of liver abnormality increased with increasing 
dosage. Bilirubin levels were not significantly different (p<0.05) when compared with the control. Bilirubin is a 
waste product from the breakdown of red blood cells. The liver processes bilirubin so it can be excreted in stool. 
Bilirubin flows through the liver's bile ducts, dissolved in bile. Bilirubin blood levels may be elevated in people with 
impaired bile flow. This can occur in severe liver disease, gallbladder disease, or other bile system conditions. Very 
high bilirubin levels cause jaundice, in which the skin and whites of the eyes turn yellow [38]. Bilirubin can be a 
useful liver function test in people with a known bile flow problem. Higher than normal levels of direct or indirect 
bilirubin may indicate different types of liver problems. Occasionally, higher bilirubin levels may indicate an 
increased rate of destruction of red blood cells. Hence, the stable level of bilirubin in animals treated with Jobelyn® 
further supports the safety and possible hepatoprotective role of Jobelyn®. A significant decrease (p<0.05) in Urea 
concentration was observed, suggesting that Jobelyn® may have protective effects on renal function. Salawuet al. 
[27] also observed similar effects when Sorghum bicolor aqueous extract was administered to rats fed with low and 
high iron diet. This implies that the administration of Jobelyn® has no toxic effect on the kidney and may thereby 
preserve the integrity of the kidney. Urea is the major end product of protein metabolism in humans and other 
mammals. Factors which tend to increase urea excretion include increases in glomerular filtration rate, increased 
dietary protein intake, protein catabolic conditions, and water diuretic states. Factors which reduce urea excretion 
include low protein intake and conditions which result in low urine output such as dehydration), although low urea 
levels are seen during normal pregnancy. Biochemical analysis revealed significant decrease (p<0.05) in the levels 
of Hb and PCV in only the group administered 1000mg/kg which could be due to the high-dose (Table 7). The PCV 
(packed cell volume) determines the percentage of red blood cells in the plasma. During Pregnancy, however, 
decreased hematocrit levels are observed, especially in the last trimester as plasma volume increases. Haemodilution 
occurs physiologically in pregnancy [39]. This may result in lower haemoglobin concentrations than in the non-
pregnant state. Sorghum contains such hard-to-find nutrients as iron, calcium and potassium. In the past, doctors 
prescribed sorghum as a daily supplement for those low in these nutrients. No significant difference was observed in 
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the levels of triglyceride, total cholesterol and high density cholesterol. Implying that Jobelyn® poses no threat on 
the body as relates to diseases caused by increased cholesterol such as atherosclerosis. In addition to the high content 
of anti-inflammatory phenolic compounds, sorghum contains several groups of bioactive compounds with the 
capacity to induce pro-inflammatory immune responses. Water-soluble beta-glucans are found in sorghum that 
showed biologically active beta-glucans capable of initiating macrophage activation. 
 
 
 
FIGURE 1. Effects of Jobelyn on plasma of pregnant albino rats. ALT = Alanine aminotransferase, ALP = Alkaline phosphatise, 
AST = Aspartate transaminase, TP = Total protein, ALB = Albumin. Values are presented as mean ± standard error of mean 
(SEM) of 8 replicates; *significant at p < 0.05 as compared with control 
 
 
FIGURE 2. Effects of Jobelyn on Kidney functions of pregnant albino rats. Values are presented as mean ± standard error of 
mean (SEM) of 8 replicates; *significant at p < 0.05 as compared with control. 
RECOMMENDATION 
Jobelyn® should be subjected to further analysis to clearly ascertain the mechanisms involved in its suggested 
haematocrit boosting property, as well as its proposed hepatoprotective and renal protective property, with emphasis 
on pregnant women. This would help further confirm the safety of the drug for consumption by pregnant women. 
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 FIGURE 3. Photomicrograph of liver tissues of rat (H&E x 400)(A) with normal features in the control (B) treated with 
250mg/kg bodyweight of Jobelyn® Showing mild to moderate portal inflammation, H&E x 400 (C) treated 500 mg/kg 
bodyweight of Jobelyn®(D)treated with  1000 mg/kg bodyweight of Jobelyn®. 
CONCLUSION 
In conclusion, Jobelyn may enhance liver and kidney functions in pregnant women when taken at an appropriate 
dose. It may also boost haematocrit level, and thus could be ideal for intake by pregnant women. 
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